178 filings
8-K
ARAV
Aravive Inc
17 Jan 24
Entry into a Material Definitive Agreement
4:22pm
8-K
ARAV
Aravive Inc
3 Nov 23
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
ARAV
Aravive Inc
3 Oct 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
ARAV
Aravive Inc
19 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:10pm
8-K
ARAV
Aravive Inc
2 Aug 23
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
4:18pm
8-K
f1ezpv309y
5 Jun 23
Regulation FD Disclosure
4:05pm
8-K
4yba0jgt82o
25 May 23
Regulation FD Disclosure
5:00pm
8-K
cdd dnjt1e
16 May 23
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
7:05am
8-K
uv72jxn 00nl
10 May 23
Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates
4:05pm
8-K
je2u6p dysk
11 Apr 23
Aravive Appoints Carolina Petrini as Chief Commercial Officer
7:10am
8-K
hld6dv8j t3
15 Mar 23
Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
7:10am
8-K
w4q0gsd4
28 Feb 23
Aravive Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer
4:11pm
8-K
pe2ia2c1
13 Feb 23
Regulation FD Disclosure
5:06pm
8-K
qk4pnsr8zo56xdrdqlcl
6 Feb 23
Departure of Directors or Certain Officers
5:09pm
8-K
twvu6b8
18 Jan 23
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
upg5u1lzx
4 Jan 23
Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer
7:05am
8-K
40x6wdz6iree2xbp0
3 Jan 23
Other Events
4:06pm
8-K
2xgi7d ht
29 Nov 22
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
7:05am
8-K
e6knox
16 Nov 22
Other Events
7:05am
8-K
yl1slf
10 Nov 22
Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
7:05am